Evaluation of the use of oseltamivir prophylaxis in the control of influenza outbreaks in long-term care facilities in Alberta, Canada: a retrospective provincial database analysis.
Identifieur interne : 000167 ( Main/Exploration ); précédent : 000166; suivant : 000168Evaluation of the use of oseltamivir prophylaxis in the control of influenza outbreaks in long-term care facilities in Alberta, Canada: a retrospective provincial database analysis.
Auteurs : Ming Ye [Canada] ; Angela Jacobs [Canada] ; Muhammad Naeem Khan [Canada] ; Joy Jaipaul [Canada] ; Joanna Oda [Canada] ; Marcia Johnson [Canada] ; Alexander Doroshenko [Canada]Source :
- BMJ open [ 2044-6055 ] ; 2016.
Descripteurs français
- KwdFr :
- Adulte (MeSH), Alberta (épidémiologie), Antiviraux (usage thérapeutique), Femelle (MeSH), Grippe humaine (prévention et contrôle), Grippe humaine (traitement médicamenteux), Grippe humaine (épidémiologie), Humains (MeSH), Mâle (MeSH), Oséltamivir (usage thérapeutique), Processus politique (MeSH), Résultat thérapeutique (MeSH), Soins de longue durée (MeSH), Vaccins antigrippaux (usage thérapeutique), Épidémies de maladies (prévention et contrôle), Établissements de soins qualifiés (MeSH), Études rétrospectives (MeSH), Évaluation de programme (MeSH).
- MESH :
- prévention et contrôle : Grippe humaine, Épidémies de maladies.
- traitement médicamenteux : Grippe humaine.
- usage thérapeutique : Antiviraux, Oséltamivir, Vaccins antigrippaux.
- épidémiologie : Alberta, Grippe humaine.
- Adulte, Femelle, Humains, Mâle, Processus politique, Résultat thérapeutique, Soins de longue durée, Établissements de soins qualifiés, Études rétrospectives, Évaluation de programme.
English descriptors
- KwdEn :
- Adult (MeSH), Alberta (epidemiology), Antiviral Agents (therapeutic use), Disease Outbreaks (prevention & control), Female (MeSH), Humans (MeSH), Influenza Vaccines (therapeutic use), Influenza, Human (drug therapy), Influenza, Human (epidemiology), Influenza, Human (prevention & control), Long-Term Care (MeSH), Male (MeSH), Oseltamivir (therapeutic use), Policy Making (MeSH), Program Evaluation (MeSH), Retrospective Studies (MeSH), Skilled Nursing Facilities (MeSH), Treatment Outcome (MeSH).
- MESH :
- chemical , therapeutic use : Antiviral Agents, Influenza Vaccines, Oseltamivir.
- drug therapy : Influenza, Human.
- epidemiology : Alberta, Influenza, Human.
- prevention & control : Disease Outbreaks, Influenza, Human.
- Adult, Female, Humans, Long-Term Care, Male, Policy Making, Program Evaluation, Retrospective Studies, Skilled Nursing Facilities, Treatment Outcome.
Abstract
OBJECTIVES
To evaluate the impact of oseltamivir prophylaxis in the management and control of influenza outbreaks in long-term care facilities in Alberta, Canada.
SETTING AND PARTICIPANTS
Long-term care facilities where 127 influenza outbreaks were reported to public health authorities in Alberta, Canada, during two influenza seasons from 2013 to 2015.
DESIGN AND OUTCOME MEASURES
Using routinely collected surveillance and administrative data, we examined the association between decision-making time for oseltamivir recommendation as prophylaxis strategy for influenza outbreaks in long-term care facilities (explanatory variable) and the duration of an influenza outbreak, the postprophylaxis risk of influenza-like illness and hospitalisation among residents of long-term care facilities in Alberta (outcome variables) using multivariable linear and Poisson regression models.
RESULTS
Oseltamivir prophylaxis decision-making time was positively associated with the postintervention duration of an outbreak, with a 1-day delay in making decision on oseltamivir prophylaxis associated with 2.22 (95% CI 1.37 to 3.06) more days of the duration of an outbreak after controlling for potential confounding effect of the number of residents at risk at intervention, outbreak progression time, prevalence of influenza-like illness during outbreak progression, facility location, presence of mixed strain and based on optimal timing of oseltamivir prophylaxis. Although not statistically significant, a 1-day delay in making decision on oseltamivir prophylaxis was associated with a 5% (95% CI -1% to 11%) increase in the postintervention risk of influenza-like illness, and a 6% (95% CI -8% to 22%) increase in the postintervention risk of hospitalisation after controlling for the same potential confounders.
CONCLUSIONS
Our study demonstrated benefits of using oseltamivir prophylaxis to shorten the duration of influenza outbreaks; however, there were no significant differences in the influenza-like illness and hospitalisation risk occurring after the intervention. Surveillance data may offer means of rapid evaluation of oseltamivir prophylaxis in long-term care facilities as a public health measure.
DOI: 10.1136/bmjopen-2016-011686
PubMed: 27381211
PubMed Central: PMC4947728
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Evaluation of the use of oseltamivir prophylaxis in the control of influenza outbreaks in long-term care facilities in Alberta, Canada: a retrospective provincial database analysis.</title><author><name sortKey="Ye, Ming" sort="Ye, Ming" uniqKey="Ye M" first="Ming" last="Ye">Ming Ye</name><affiliation wicri:level="1"><nlm:affiliation>School of Public Health, University of Alberta, Edmonton, Alberta, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>School of Public Health, University of Alberta, Edmonton, Alberta</wicri:regionArea><wicri:noRegion>Alberta</wicri:noRegion></affiliation></author><author><name sortKey="Jacobs, Angela" sort="Jacobs, Angela" uniqKey="Jacobs A" first="Angela" last="Jacobs">Angela Jacobs</name><affiliation wicri:level="1"><nlm:affiliation>Alberta Health Services, Edmonton, Alberta, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Alberta Health Services, Edmonton, Alberta</wicri:regionArea><wicri:noRegion>Alberta</wicri:noRegion></affiliation></author><author><name sortKey="Khan, Muhammad Naeem" sort="Khan, Muhammad Naeem" uniqKey="Khan M" first="Muhammad Naeem" last="Khan">Muhammad Naeem Khan</name><affiliation wicri:level="1"><nlm:affiliation>Alberta Health Services, Edmonton, Alberta, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Alberta Health Services, Edmonton, Alberta</wicri:regionArea><wicri:noRegion>Alberta</wicri:noRegion></affiliation></author><author><name sortKey="Jaipaul, Joy" sort="Jaipaul, Joy" uniqKey="Jaipaul J" first="Joy" last="Jaipaul">Joy Jaipaul</name><affiliation wicri:level="1"><nlm:affiliation>Alberta Health Services, Edmonton, Alberta, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Alberta Health Services, Edmonton, Alberta</wicri:regionArea><wicri:noRegion>Alberta</wicri:noRegion></affiliation></author><author><name sortKey="Oda, Joanna" sort="Oda, Joanna" uniqKey="Oda J" first="Joanna" last="Oda">Joanna Oda</name><affiliation wicri:level="1"><nlm:affiliation>Alberta Health Services, Edmonton, Alberta, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Alberta Health Services, Edmonton, Alberta</wicri:regionArea><wicri:noRegion>Alberta</wicri:noRegion></affiliation></author><author><name sortKey="Johnson, Marcia" sort="Johnson, Marcia" uniqKey="Johnson M" first="Marcia" last="Johnson">Marcia Johnson</name><affiliation wicri:level="1"><nlm:affiliation>Alberta Health Services, Edmonton, Alberta, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Alberta Health Services, Edmonton, Alberta</wicri:regionArea><wicri:noRegion>Alberta</wicri:noRegion></affiliation></author><author><name sortKey="Doroshenko, Alexander" sort="Doroshenko, Alexander" uniqKey="Doroshenko A" first="Alexander" last="Doroshenko">Alexander Doroshenko</name><affiliation wicri:level="1"><nlm:affiliation>Alberta Health Services, Edmonton, Alberta, Canada Faculty of Medicine and Dentistry, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Alberta Health Services, Edmonton, Alberta, Canada Faculty of Medicine and Dentistry, Department of Medicine, University of Alberta, Edmonton, Alberta</wicri:regionArea><wicri:noRegion>Alberta</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27381211</idno><idno type="pmid">27381211</idno><idno type="doi">10.1136/bmjopen-2016-011686</idno><idno type="pmc">PMC4947728</idno><idno type="wicri:Area/Main/Corpus">000151</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000151</idno><idno type="wicri:Area/Main/Curation">000151</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000151</idno><idno type="wicri:Area/Main/Exploration">000151</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Evaluation of the use of oseltamivir prophylaxis in the control of influenza outbreaks in long-term care facilities in Alberta, Canada: a retrospective provincial database analysis.</title><author><name sortKey="Ye, Ming" sort="Ye, Ming" uniqKey="Ye M" first="Ming" last="Ye">Ming Ye</name><affiliation wicri:level="1"><nlm:affiliation>School of Public Health, University of Alberta, Edmonton, Alberta, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>School of Public Health, University of Alberta, Edmonton, Alberta</wicri:regionArea><wicri:noRegion>Alberta</wicri:noRegion></affiliation></author><author><name sortKey="Jacobs, Angela" sort="Jacobs, Angela" uniqKey="Jacobs A" first="Angela" last="Jacobs">Angela Jacobs</name><affiliation wicri:level="1"><nlm:affiliation>Alberta Health Services, Edmonton, Alberta, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Alberta Health Services, Edmonton, Alberta</wicri:regionArea><wicri:noRegion>Alberta</wicri:noRegion></affiliation></author><author><name sortKey="Khan, Muhammad Naeem" sort="Khan, Muhammad Naeem" uniqKey="Khan M" first="Muhammad Naeem" last="Khan">Muhammad Naeem Khan</name><affiliation wicri:level="1"><nlm:affiliation>Alberta Health Services, Edmonton, Alberta, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Alberta Health Services, Edmonton, Alberta</wicri:regionArea><wicri:noRegion>Alberta</wicri:noRegion></affiliation></author><author><name sortKey="Jaipaul, Joy" sort="Jaipaul, Joy" uniqKey="Jaipaul J" first="Joy" last="Jaipaul">Joy Jaipaul</name><affiliation wicri:level="1"><nlm:affiliation>Alberta Health Services, Edmonton, Alberta, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Alberta Health Services, Edmonton, Alberta</wicri:regionArea><wicri:noRegion>Alberta</wicri:noRegion></affiliation></author><author><name sortKey="Oda, Joanna" sort="Oda, Joanna" uniqKey="Oda J" first="Joanna" last="Oda">Joanna Oda</name><affiliation wicri:level="1"><nlm:affiliation>Alberta Health Services, Edmonton, Alberta, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Alberta Health Services, Edmonton, Alberta</wicri:regionArea><wicri:noRegion>Alberta</wicri:noRegion></affiliation></author><author><name sortKey="Johnson, Marcia" sort="Johnson, Marcia" uniqKey="Johnson M" first="Marcia" last="Johnson">Marcia Johnson</name><affiliation wicri:level="1"><nlm:affiliation>Alberta Health Services, Edmonton, Alberta, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Alberta Health Services, Edmonton, Alberta</wicri:regionArea><wicri:noRegion>Alberta</wicri:noRegion></affiliation></author><author><name sortKey="Doroshenko, Alexander" sort="Doroshenko, Alexander" uniqKey="Doroshenko A" first="Alexander" last="Doroshenko">Alexander Doroshenko</name><affiliation wicri:level="1"><nlm:affiliation>Alberta Health Services, Edmonton, Alberta, Canada Faculty of Medicine and Dentistry, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Alberta Health Services, Edmonton, Alberta, Canada Faculty of Medicine and Dentistry, Department of Medicine, University of Alberta, Edmonton, Alberta</wicri:regionArea><wicri:noRegion>Alberta</wicri:noRegion></affiliation></author></analytic><series><title level="j">BMJ open</title><idno type="eISSN">2044-6055</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term><term>Alberta (epidemiology)</term><term>Antiviral Agents (therapeutic use)</term><term>Disease Outbreaks (prevention & control)</term><term>Female (MeSH)</term><term>Humans (MeSH)</term><term>Influenza Vaccines (therapeutic use)</term><term>Influenza, Human (drug therapy)</term><term>Influenza, Human (epidemiology)</term><term>Influenza, Human (prevention & control)</term><term>Long-Term Care (MeSH)</term><term>Male (MeSH)</term><term>Oseltamivir (therapeutic use)</term><term>Policy Making (MeSH)</term><term>Program Evaluation (MeSH)</term><term>Retrospective Studies (MeSH)</term><term>Skilled Nursing Facilities (MeSH)</term><term>Treatment Outcome (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte (MeSH)</term><term>Alberta (épidémiologie)</term><term>Antiviraux (usage thérapeutique)</term><term>Femelle (MeSH)</term><term>Grippe humaine (prévention et contrôle)</term><term>Grippe humaine (traitement médicamenteux)</term><term>Grippe humaine (épidémiologie)</term><term>Humains (MeSH)</term><term>Mâle (MeSH)</term><term>Oséltamivir (usage thérapeutique)</term><term>Processus politique (MeSH)</term><term>Résultat thérapeutique (MeSH)</term><term>Soins de longue durée (MeSH)</term><term>Vaccins antigrippaux (usage thérapeutique)</term><term>Épidémies de maladies (prévention et contrôle)</term><term>Établissements de soins qualifiés (MeSH)</term><term>Études rétrospectives (MeSH)</term><term>Évaluation de programme (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Influenza Vaccines</term><term>Oseltamivir</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Alberta</term><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Disease Outbreaks</term><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Grippe humaine</term><term>Épidémies de maladies</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term><term>Oséltamivir</term><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Alberta</term><term>Grippe humaine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Female</term><term>Humans</term><term>Long-Term Care</term><term>Male</term><term>Policy Making</term><term>Program Evaluation</term><term>Retrospective Studies</term><term>Skilled Nursing Facilities</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Processus politique</term><term>Résultat thérapeutique</term><term>Soins de longue durée</term><term>Établissements de soins qualifiés</term><term>Études rétrospectives</term><term>Évaluation de programme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>OBJECTIVES</b></p><p>To evaluate the impact of oseltamivir prophylaxis in the management and control of influenza outbreaks in long-term care facilities in Alberta, Canada.</p></div><div type="abstract" xml:lang="en"><p><b>SETTING AND PARTICIPANTS</b></p><p>Long-term care facilities where 127 influenza outbreaks were reported to public health authorities in Alberta, Canada, during two influenza seasons from 2013 to 2015.</p></div><div type="abstract" xml:lang="en"><p><b>DESIGN AND OUTCOME MEASURES</b></p><p>Using routinely collected surveillance and administrative data, we examined the association between decision-making time for oseltamivir recommendation as prophylaxis strategy for influenza outbreaks in long-term care facilities (explanatory variable) and the duration of an influenza outbreak, the postprophylaxis risk of influenza-like illness and hospitalisation among residents of long-term care facilities in Alberta (outcome variables) using multivariable linear and Poisson regression models.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>Oseltamivir prophylaxis decision-making time was positively associated with the postintervention duration of an outbreak, with a 1-day delay in making decision on oseltamivir prophylaxis associated with 2.22 (95% CI 1.37 to 3.06) more days of the duration of an outbreak after controlling for potential confounding effect of the number of residents at risk at intervention, outbreak progression time, prevalence of influenza-like illness during outbreak progression, facility location, presence of mixed strain and based on optimal timing of oseltamivir prophylaxis. Although not statistically significant, a 1-day delay in making decision on oseltamivir prophylaxis was associated with a 5% (95% CI -1% to 11%) increase in the postintervention risk of influenza-like illness, and a 6% (95% CI -8% to 22%) increase in the postintervention risk of hospitalisation after controlling for the same potential confounders.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>Our study demonstrated benefits of using oseltamivir prophylaxis to shorten the duration of influenza outbreaks; however, there were no significant differences in the influenza-like illness and hospitalisation risk occurring after the intervention. Surveillance data may offer means of rapid evaluation of oseltamivir prophylaxis in long-term care facilities as a public health measure.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27381211</PMID><DateCompleted><Year>2018</Year><Month>01</Month><Day>01</Day></DateCompleted><DateRevised><Year>2019</Year><Month>02</Month><Day>02</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2044-6055</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>7</Issue><PubDate><Year>2016</Year><Month>07</Month><Day>05</Day></PubDate></JournalIssue><Title>BMJ open</Title><ISOAbbreviation>BMJ Open</ISOAbbreviation></Journal><ArticleTitle>Evaluation of the use of oseltamivir prophylaxis in the control of influenza outbreaks in long-term care facilities in Alberta, Canada: a retrospective provincial database analysis.</ArticleTitle><Pagination><MedlinePgn>e011686</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjopen-2016-011686</ELocationID><Abstract><AbstractText Label="OBJECTIVES">To evaluate the impact of oseltamivir prophylaxis in the management and control of influenza outbreaks in long-term care facilities in Alberta, Canada.</AbstractText><AbstractText Label="SETTING AND PARTICIPANTS">Long-term care facilities where 127 influenza outbreaks were reported to public health authorities in Alberta, Canada, during two influenza seasons from 2013 to 2015.</AbstractText><AbstractText Label="DESIGN AND OUTCOME MEASURES">Using routinely collected surveillance and administrative data, we examined the association between decision-making time for oseltamivir recommendation as prophylaxis strategy for influenza outbreaks in long-term care facilities (explanatory variable) and the duration of an influenza outbreak, the postprophylaxis risk of influenza-like illness and hospitalisation among residents of long-term care facilities in Alberta (outcome variables) using multivariable linear and Poisson regression models.</AbstractText><AbstractText Label="RESULTS">Oseltamivir prophylaxis decision-making time was positively associated with the postintervention duration of an outbreak, with a 1-day delay in making decision on oseltamivir prophylaxis associated with 2.22 (95% CI 1.37 to 3.06) more days of the duration of an outbreak after controlling for potential confounding effect of the number of residents at risk at intervention, outbreak progression time, prevalence of influenza-like illness during outbreak progression, facility location, presence of mixed strain and based on optimal timing of oseltamivir prophylaxis. Although not statistically significant, a 1-day delay in making decision on oseltamivir prophylaxis was associated with a 5% (95% CI -1% to 11%) increase in the postintervention risk of influenza-like illness, and a 6% (95% CI -8% to 22%) increase in the postintervention risk of hospitalisation after controlling for the same potential confounders.</AbstractText><AbstractText Label="CONCLUSIONS">Our study demonstrated benefits of using oseltamivir prophylaxis to shorten the duration of influenza outbreaks; however, there were no significant differences in the influenza-like illness and hospitalisation risk occurring after the intervention. Surveillance data may offer means of rapid evaluation of oseltamivir prophylaxis in long-term care facilities as a public health measure.</AbstractText><CopyrightInformation>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Ming</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>School of Public Health, University of Alberta, Edmonton, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jacobs</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Alberta Health Services, Edmonton, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Muhammad Naeem</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>Alberta Health Services, Edmonton, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jaipaul</LastName><ForeName>Joy</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Alberta Health Services, Edmonton, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oda</LastName><ForeName>Joanna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Alberta Health Services, Edmonton, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Marcia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Alberta Health Services, Edmonton, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doroshenko</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Alberta Health Services, Edmonton, Alberta, Canada Faculty of Medicine and Dentistry, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>07</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Open</MedlineTA><NlmUniqueID>101552874</NlmUniqueID><ISSNLinking>2044-6055</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>20O93L6F9H</RegistryNumber><NameOfSubstance UI="D053139">Oseltamivir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000416" MajorTopicYN="N">Alberta</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008134" MajorTopicYN="Y">Long-Term Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053139" MajorTopicYN="N">Oseltamivir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011050" MajorTopicYN="N">Policy Making</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015397" MajorTopicYN="N">Program Evaluation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012866" MajorTopicYN="N">Skilled Nursing Facilities</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">influenza</Keyword><Keyword MajorTopicYN="Y">long-term care facility</Keyword><Keyword MajorTopicYN="Y">oseltamivir</Keyword><Keyword MajorTopicYN="Y">outbreak</Keyword><Keyword MajorTopicYN="Y">prophylaxis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>1</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27381211</ArticleId><ArticleId IdType="pii">bmjopen-2016-011686</ArticleId><ArticleId IdType="doi">10.1136/bmjopen-2016-011686</ArticleId><ArticleId IdType="pmc">PMC4947728</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Infection. 2015 Feb;43(1):73-81</Citation><ArticleIdList><ArticleId IdType="pubmed">25403263</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2012;7(10):e46509</Citation><ArticleIdList><ArticleId IdType="pubmed">23082123</ArticleId></ArticleIdList></Reference><Reference><Citation>Euro Surveill. 2015 Jan 29;20(4):null</Citation><ArticleIdList><ArticleId IdType="pubmed">25655053</ArticleId></ArticleIdList></Reference><Reference><Citation>Influenza Other Respir Viruses. 2009 Jan;3(1):15-20</Citation><ArticleIdList><ArticleId IdType="pubmed">19453437</ArticleId></ArticleIdList></Reference><Reference><Citation>Infect Control Hosp Epidemiol. 1999 Sep;20(9):629-37</Citation><ArticleIdList><ArticleId IdType="pubmed">10501266</ArticleId></ArticleIdList></Reference><Reference><Citation>J Hosp Infect. 2008 Jan;68(1):83-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17945389</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Themes Epidemiol. 2014 Sep 10;11:13</Citation><ArticleIdList><ArticleId IdType="pubmed">25210532</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Prev Med. 1995 Nov-Dec;11(6 Suppl):6-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8776135</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Geriatr Soc. 2002 Apr;50(4):608-16</Citation><ArticleIdList><ArticleId IdType="pubmed">11982659</ArticleId></ArticleIdList></Reference><Reference><Citation>Infect Control Hosp Epidemiol. 2011 Oct;32(10):990-7</Citation><ArticleIdList><ArticleId IdType="pubmed">21931249</ArticleId></ArticleIdList></Reference><Reference><Citation>Can J Infect Dis Med Microbiol. 2012 Winter;23(4):e79-92</Citation><ArticleIdList><ArticleId IdType="pubmed">24294283</ArticleId></ArticleIdList></Reference><Reference><Citation>Can J Infect Dis Med Microbiol. 2015 Jan-Feb;26(1):e1-4</Citation><ArticleIdList><ArticleId IdType="pubmed">25798158</ArticleId></ArticleIdList></Reference><Reference><Citation>Can Commun Dis Rep. 2001 Mar 1;27(5):37-40</Citation><ArticleIdList><ArticleId IdType="pubmed">11260987</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2004 Aug 15;39(4):459-64</Citation><ArticleIdList><ArticleId IdType="pubmed">15356805</ArticleId></ArticleIdList></Reference><Reference><Citation>Influenza Other Respir Viruses. 2014 Jan;8(1):74-82</Citation><ArticleIdList><ArticleId IdType="pubmed">24373292</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Health Syst Pharm. 2001 Jun 15;58(12):1133-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11449857</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2009 Apr 15;48(8):1003-32</Citation><ArticleIdList><ArticleId IdType="pubmed">19281331</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Infect Control. 2013 Aug;41(8):743-5</Citation><ArticleIdList><ArticleId IdType="pubmed">23790670</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Canada</li></country></list><tree><country name="Canada"><noRegion><name sortKey="Ye, Ming" sort="Ye, Ming" uniqKey="Ye M" first="Ming" last="Ye">Ming Ye</name></noRegion><name sortKey="Doroshenko, Alexander" sort="Doroshenko, Alexander" uniqKey="Doroshenko A" first="Alexander" last="Doroshenko">Alexander Doroshenko</name><name sortKey="Jacobs, Angela" sort="Jacobs, Angela" uniqKey="Jacobs A" first="Angela" last="Jacobs">Angela Jacobs</name><name sortKey="Jaipaul, Joy" sort="Jaipaul, Joy" uniqKey="Jaipaul J" first="Joy" last="Jaipaul">Joy Jaipaul</name><name sortKey="Johnson, Marcia" sort="Johnson, Marcia" uniqKey="Johnson M" first="Marcia" last="Johnson">Marcia Johnson</name><name sortKey="Khan, Muhammad Naeem" sort="Khan, Muhammad Naeem" uniqKey="Khan M" first="Muhammad Naeem" last="Khan">Muhammad Naeem Khan</name><name sortKey="Oda, Joanna" sort="Oda, Joanna" uniqKey="Oda J" first="Joanna" last="Oda">Joanna Oda</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeCanadaV4/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000167 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000167 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeCanadaV4
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:27381211
|texte= Evaluation of the use of oseltamivir prophylaxis in the control of influenza outbreaks in long-term care facilities in Alberta, Canada: a retrospective provincial database analysis.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:27381211" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeCanadaV4
| This area was generated with Dilib version V0.6.35. |  |